Clinical Trial Update: TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating SD-101 (TLR9 agonist) combined with Ibrutinib and radiation therapy in relapsed or refractory follicular lymphoma (grades 1-3A), wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Ibrutinib (Imbruvica) (Ibrutinib)
• SD-101

Snippet

Sponsor: Robert Lowsky | Conditions: Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-10-16